ClinicalTrials.gg

Program

bremzalerbart

Its studies are mostly in Conjunctivitis, Allergic · Rhinitis, Allergic, led by Regeneron Pharmaceuticals.

Furthest: phase 3, since Dec 23, 20204 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Regeneron Pharmaceuticals40 open or runningphase 3since Dec 23, 2020Dec 23, 2020none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 23, 2020First study: phase 3 study in Rhinitis, AllergicFirst studyNCT04709575 · 353 enrolled · United States, Belgium, Canada and more
  2. Jun 20, 2022Phase 2 study in Rhinitis, AllergicNCT05430919 · 217 enrolled · Canada
  3. Sep 17, 2024Phase 3 study in Conjunctivitis, AllergicNCT06602739 · 54 enrolled · United States, Canada
  4. Dec 17, 2025Phase 3 study in Conjunctivitis, AllergicNCT07309432 · 24 enrolled · United States

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07309432Conjunctivitis, Allergic · United States3TerminatedMay 2, 202624
NCT06602739Conjunctivitis, Allergic · United States, Canada3CompletedApr 23, 202554
NCT05430919Rhinitis, Allergic · Canada2CompletedJul 31, 2023217
NCT04709575Rhinitis, Allergic · United States, Belgium, Canada and more3CompletedAug 24, 2021353

How it is read

Names in the registry

  • “REGN5713”, 4 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.